Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Instituciones de las que forman parte Jefe de grupo Investigación biomédica con Células Madre de Cáncer Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Matilde Lleonart Pajarin LinkedIn Twitter Orcid Email Instituciones de las que forman parte Jefe de grupo Investigación biomédica con Células Madre de Cáncer Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Proyectos Identificación de nuevas dianas terapéuticas basadas en micro-RNAs sobreexpresados en cáncer IP: Matilde Lleonart Pajarin Colaboradores: Marc Pellicer Sarasa, Marta Garrido Pontnou, Carmela Iglesias i Felip Entidad financiadora: Instituto de Salud Carlos III Financiación: 147015 Referencia: PI09/02193 Duración: 01/01/2010 - 30/04/2013 Oncología y Patología Molecular IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 39520 Referencia: 2009 SGR 604 Duración: 01/01/2010 - 30/04/2014 Cirp function as a chaperone molecule interacting with RNA and microRNA and microRNAs IP: Santiago Ramon y Cajal Agüeras Colaboradores: Matilde Lleonart Pajarin Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 7600 Referencia: 2007 BE-1 00296 Duración: 20/08/2007 - 20/12/2007 Identificación y caracterización de nuevos genes que inmortalizan células primarias y su papel en tumores humanos IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: Instituto de Salud Carlos III Financiación: 86052 Referencia: FI06/00608 Duración: 08/02/2007 - 07/02/2011 Paginación Primera página « Página anterior ‹ … Página 4 Página 5 Página actual 6 Página 7 Página 8 Siguiente página › Última página »
